DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in BRCA-mutant ovarian cancer.
• Limited efficacy in the broader ovarian cancer population due to low BRCA mutation rates.
• Need for novel therapeutic strategies beyond PARP inhibition.

Purpose of the Study:

• To investigate the therapeutic potential of poly(ADP-ribose) glycohydrolase (PARG) inhibitors in ovarian cancer.
• To identify mechanisms of sensitivity and resistance to PARG inhibitors.
• To explore combination strategies with existing therapies.

Main Methods:

• Screening of ovarian cancer cell lines and ex vivo patient-derived models with a PARG inhibitor.
• Analysis of DNA replication dynamics and fork stalling.
• Synthetic lethality studies with CHK1 inhibitors.

Main Results:

• A subset of ovarian cancer models demonstrated sensitivity to PARG inhibitors.
• Sensitivity was linked to DNA replication vulnerabilities and persistent fork stalling.
• PARG inhibition showed synthetic lethality with CHK1 inhibitors, expanding the sensitive population.
• PARG and PARP inhibitor sensitivity were mutually exclusive.

Conclusions:

• PARG inhibitors represent a promising therapeutic strategy for ovarian cancer.
• PARG inhibitors can overcome resistance to PARP inhibitors by targeting distinct vulnerabilities.
• Combination therapy with CHK1 inhibitors may broaden the applicability of PARG inhibitors.